Studies Find Limited Support For Genotyping-Guided Warfarin Dosing
This article was originally published in The Gray Sheet
The overall message of three trials published recently in The New England Journal of Medicine: “This pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing,” according to an editorial also in NEJM.
You may also be interested in...
FDA-approved labels for more than 100 drugs feature pharmacogenomic biomarker data, but only one-sixth of those biomarkers are supported by data showing a clear association with health benefits, a JAMA study found. Researchers recommend stricter standards and a standardized pharmacogenomics section of labeling.
“Why are insurers so reluctant to get enthusiastic and really embrace molecular diagnostics?” asked the director of CMS’ coverage and analysis group at a recent cancer diagnostics symposium. “Because half the time we have no idea what on earth we’re paying for.”
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30% reduction in hospitalization rates from any cause within six months of starting the drug